Treating Alzheimer’s patients as early as possible — when symptoms and brain pathology are mildest — provides a better chance of slowing cognitive decline, a large study of an experimental Alzheimer’s drug presented Monday suggests.The study of 1,736 patients reported that the drug, donanemab, made by Eli Lilly, can modestly slow the progression of memory…
